Magnetic Nanoparticles Enhance Amphotericin B Delivery Against Leishmaniasis with Reduced Toxicity

Researchers have developed a breakthrough magnetic nanoparticle system that significantly enhances the targeted delivery of amphotericin BView drug details against Leishmania amazonensis (search)Search target, the causative agent of a severe form of cutaneous leishmaniasis (search)Search disease. The innovative approach combines bacterial magnetite nanoparticles with alternating magnetic field (AMF) technology to improve drug efficacy while reducing toxicity concerns.

The study, published in Scientific Reports, addresses critical challenges in leishmaniasis (search)Search disease treatment, where current therapies suffer from high toxicity, treatment failures, and drug resistance. Leishmaniasis affects more than 12 million people worldwide, with an estimated 1 billion people at risk of infection, making it a significant neglected tropical disease.

Magnetic Enhancement Dramatically Improves Efficacy

The research team utilized magnetosomes—biological magnetic nanoparticles produced by magnetotactic bacteria Magnetovibrio blakemorei (search)Search target strain MV-1—as drug carriers. These nanobiomagnetite particles were functionalized with poly-L-lysine and loaded with amphotericin BView drug details to create the BMs-PLL-AmB (search)Search drug formulation.

The results demonstrated remarkable efficacy against L. amazonensis promastigotes, with the nanoformulation achieving an IC50 of 3.13 μg/mL. However, the most significant breakthrough came when researchers applied alternating magnetic fields to enhance drug release and targeting.

"AMF application significantly decreased the cell viability of L. amazonensis promastigotes when treated with BMs-PLL-AmB (search)Search drug," the researchers reported. At the previously determined IC50 concentration, AMF exposure reduced parasite viability to just 11.2 ± 8.6%, compared to 50% without magnetic field application.

The magnetic enhancement also improved the effectiveness of lower concentrations. The ½ IC50 concentration, which previously showed 89% parasite viability, achieved 42.45 ± 9.0% viability with AMF application—matching the efficacy of the full IC50 dose without magnetic enhancement.

Superior Biocompatibility Profile

One of the most promising aspects of the nanobiomagnetite system is its excellent safety profile. Extensive cytotoxicity testing on human keratinocytes (HaCaT), human fibroblasts, and mouse macrophages showed that all cell types maintained robust viability above 80% for all tested concentrations up to 25 μg/mL during 72 hours of treatment.

The nanoparticles demonstrated no hemolytic activity even at concentrations up to 250 μg/mL—approximately 80 times higher than the effective anti-parasitic dose. This finding is particularly significant given that previous studies with other magnetic nanoparticles showed some hemolytic effects at much lower concentrations.

"The absence of hemolytic effects observed in our study supports the biocompatibility and safety profile of the functionalized BMs, suggesting their potential suitability for biomedical applications," the researchers noted.

Mechanism and Morphological Changes

Transmission electron microscopy revealed dramatic morphological changes in treated parasites, particularly when magnetic fields were applied. Parasites treated with BMs-PLL-AmB (search)Search drug and exposed to AMF showed diverse cellular inclusions, organelle alterations, and cytoplasm extravasation. At higher concentrations with AMF application, cells exhibited severe morphological damage with significant cytoplasm loss.

The enhanced drug release under magnetic field conditions was attributed to nanoparticle rotation (Brown relaxation) rather than hyperthermia effects. Previous studies by the research group showed that AMF application increased amphotericin BView drug details release from 15.0 ± 1.2% under standard conditions to 53.8 ± 6.2% with magnetic field exposure.

Sustainable Nanotechnology Approach

The use of biological magnetosomes offers significant advantages over synthetic magnetic nanoparticles. As naturally produced structures from magnetotactic bacteria, they align with green nanotechnology principles and reduce environmental impact compared to chemically synthesized alternatives.

The magnetosomes' biological membrane provides natural oxidation protection and facilitates molecule anchoring without requiring additional coating steps necessary for synthetic nanoparticles. This inherent biocompatibility, combined with their magnetic properties and functionalization potential, makes them versatile platforms for targeted drug delivery.

Clinical Translation Potential

The research addresses a critical unmet medical need in leishmaniasis (search)Search disease treatment, particularly for infections caused by L. amazonensis, which is associated with anergic diffuse cutaneous leishmaniasis (search)Search disease (ADCL)—a rare but severe form characterized by treatment failures and frequent relapses.

Current amphotericin BView drug details therapy, while highly effective with cure rates over 97%, requires hospitalization due to significant nephrotoxicity and high costs. The magnetic nanoparticle system offers the potential to maintain therapeutic efficacy while dramatically reducing systemic toxicity through targeted delivery.

The study's findings support the United Nations 2030 Agenda for Sustainable Development, specifically the third Sustainable Development Goal targeting the elimination of neglected tropical disease epidemics by 2030. By offering potentially cost-effective and innovative treatments with reduced environmental impact, this nanotechnology-driven solution could significantly improve healthcare access for marginalized populations affected by leishmaniasis (search)Search disease.

The research team emphasized that while these in vitro results are highly promising, additional studies including animal models are necessary to fully evaluate the system's long-term safety and clinical efficacy before potential human trials.